PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

Autor:	N. McGarvey, A. Nguyen, K. Hege, Parameswaran Hari, Corey Pelletier, K. Parikh, Matthew Gitlin
Rok vydání:	2021
Předmět:	Clinical trial Oncology medicine.medical_specialty business.industry Health Policy Internal medicine Public Health Environmental and Occupational Health medicine Refractory Multiple Myeloma business
Zdroj:	Value in Health. 24:S29-S30
ISSN:	1098-3015
DOI:	10.1016/j.jval.2021.04.150
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d8444c0e92e5d318d710f330d55a5536 https://doi.org/10.1016/j.jval.2021.04.150 Zobrazit plný text záznamu Full Text from ScienceDirect